Patients experienced mean decreases in HbA1C and weight from baseline to 6 months of -1.75% (P< 0.001) and -3.64 kg (P= 0.015), respectively, in the oral semaglutide group and -1.35% (P< 0.001) and -5.26 kg (P< 0.001), respectively, in the injectable semaglutide group.
